Sharp inks preferred partnership with CMO to reduce clinical trial complexity

By Melissa Fassbender contact

- Last updated on GMT

(Image: Gety/Anawat_s)
(Image: Gety/Anawat_s)

Related tags: CMO, Clinical trial management, Preferred partnership, Contract manufacturing

Sharp has signed a preferred partnerships agreement with an MA-based CMO to reduce “friction” for clients while decreasing the time, cost, and complexity of managing clinical trials.

Sharp – part of UDG Healthcare – provides contract packaging and clinical supply services. The company this week confirmed a preferred partner agreement with the fill/finish contract manufacturing organization (CRMO) Berkshire Sterile Manufacturing (BSM).

The agreement bolsters Sharp’s ability to provide sterile fill/finish clinical manufacturing services and gives BSM clients access to clinical trial supply and management services, including analytical testing, stability, clinical and commercial packaging, serialization, IRT services, QP services, storage as well as distribution.

Dan Gourley, senior director, Global Logistics for Sharp Clinical US, sad the companies wanted to address clients’ needs by providing sterile manufacturing through to delivery of clinical trial materials to sites. 

“This partnership simplifies our clients' supply chain in that they can work with one contracted provider for all of these activities,”​ he told us, adding that the companies have worked together in the past and have several current projects underway. 

The partnership agreement comes into effect immediately and is evergreen, Gourley said.

“Through this agreement, we are harmonizing how we work together and by having a single point of contact for our combined services, we reduce ‘friction’ for our clients,”​ he added.

As an example, Gourley explained that reciprocal vendor audits conducted by Sharp and BSM would negate the requirement for clients to conduct individual audits.

He added, “We aspire to reduce the time, cost and complexity of managing clinical trials and strategic partnerships like this are a vital element of working towards that goal.”

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Flow Cytometry Services

Flow Cytometry Services

Q2 Solutions | 01-Jun-2020 | Data Sheet

We are an established leader in flow cytometry services for clinical trials. Our technologies and solutions meet the growing global demand for enhanced...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars